
GPX4 released by ferroptotic cancer cells suppresses dendritic cell maturation and T cell priming by binding to ZP3. Blocking the GPX4-ZP3 interaction restores dendritic activity, boosts cytotoxic T cells, and enhances chemo-, radio-, and immunotherapy efficacy in preclinical cancer models.
Read more about this post…
Credits: Source
Disclaimer




Serving